JP2016503778A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016503778A5 JP2016503778A5 JP2015548640A JP2015548640A JP2016503778A5 JP 2016503778 A5 JP2016503778 A5 JP 2016503778A5 JP 2015548640 A JP2015548640 A JP 2015548640A JP 2015548640 A JP2015548640 A JP 2015548640A JP 2016503778 A5 JP2016503778 A5 JP 2016503778A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- compound according
- compound
- branched
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 16
- 229910052731 fluorine Inorganic materials 0.000 claims 7
- 239000011737 fluorine Substances 0.000 claims 5
- 125000001153 fluoro group Chemical group F* 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000003242 anti bacterial agent Substances 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 229940088710 antibiotic agent Drugs 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- -1 2 - cyclopropyl Chemical group 0.000 claims 2
- 206010003754 Atypical mycobacterial infections Diseases 0.000 claims 2
- 206010024229 Leprosy Diseases 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 201000008827 tuberculosis Diseases 0.000 claims 2
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010062207 Mycobacterial infection Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920006395 saturated elastomer Chemical group 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR12/03548 | 2012-12-21 | ||
| FR1203548A FR3000065A1 (fr) | 2012-12-21 | 2012-12-21 | Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes |
| PCT/EP2013/077732 WO2014096378A1 (fr) | 2012-12-21 | 2013-12-20 | Hétérocycles azotés saturés et n-acylés potentialisant l'activité d'un antibiotique actif contre les mycobactéries |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016503778A JP2016503778A (ja) | 2016-02-08 |
| JP2016503778A5 true JP2016503778A5 (enExample) | 2017-02-02 |
| JP6515035B2 JP6515035B2 (ja) | 2019-05-15 |
Family
ID=48521019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015548640A Active JP6515035B2 (ja) | 2012-12-21 | 2013-12-20 | マイコバクテリアに対して活性な抗生物質の活性を増強する飽和窒素及びｎ−アシル化複素環 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US9957249B2 (enExample) |
| EP (1) | EP2935212B1 (enExample) |
| JP (1) | JP6515035B2 (enExample) |
| KR (1) | KR20150138152A (enExample) |
| CN (1) | CN104955804B (enExample) |
| AU (1) | AU2013366503B2 (enExample) |
| BR (1) | BR112015014279A2 (enExample) |
| CA (1) | CA2895606A1 (enExample) |
| CL (1) | CL2015001640A1 (enExample) |
| CR (1) | CR20150319A (enExample) |
| EA (1) | EA028076B1 (enExample) |
| FR (1) | FR3000065A1 (enExample) |
| GE (1) | GEP20186857B (enExample) |
| IL (1) | IL239504B (enExample) |
| MA (1) | MA38275B1 (enExample) |
| MX (1) | MX2015008029A (enExample) |
| PE (1) | PE20151327A1 (enExample) |
| PH (1) | PH12015501427A1 (enExample) |
| SG (1) | SG11201504492UA (enExample) |
| TN (1) | TN2015000202A1 (enExample) |
| UA (1) | UA117922C2 (enExample) |
| WO (1) | WO2014096378A1 (enExample) |
| ZA (1) | ZA201503719B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3000064A1 (fr) | 2012-12-21 | 2014-06-27 | Univ Lille Ii Droit & Sante | Composes de type spiroisoxazoline ayant une activite potentialisatrice de l'activite d'un antibiotique-composition et produit pharmaceutiques comprenant de tels composes |
| KR102532198B1 (ko) | 2012-12-21 | 2023-05-11 | 얀센 바이오파마, 인코퍼레이트. | 치환된 뉴클레오사이드, 뉴클레오타이드 및 그것의 유사체 |
| UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
| EP3157915B1 (en) | 2014-06-17 | 2019-02-27 | Pfizer Inc | Substituted dihydroisoquinolinone compounds |
| HRP20211894T1 (hr) * | 2017-08-16 | 2022-08-19 | Glaxosmithkline Intellectual Property Development Limited | Novi spojevi |
| KR20200041346A (ko) * | 2017-08-16 | 2020-04-21 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 신규 화합물 |
| EP3668879B1 (en) * | 2017-08-16 | 2021-09-29 | GlaxoSmithKline Intellectual Property Development Limited | Novel compounds |
| RU2767542C1 (ru) * | 2021-05-24 | 2022-03-17 | Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) | Противотуберкулезное средство на основе 4-((гет)ароил)-3- гидрокси-1-(2-гидроксифенил)-5-(фенилтио)-1,5-дигидро-2Н-пиррол-2-онов |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4093726A (en) * | 1976-12-02 | 1978-06-06 | Abbott Laboratories | N-(2-benzimidazolyl)-piperazines |
| US4547505A (en) * | 1983-03-25 | 1985-10-15 | Degussa Aktiengesellschaft | N-Phenyl-N-'-cycloalkylalkanoylpiperazine useful as analgetics and process for its production |
| EP1118612A1 (en) * | 2000-01-21 | 2001-07-25 | Universita Degli Studi di Firenze | Piperazine derivatives possesing nootropic activity |
| TW593556B (en) * | 2002-12-27 | 2004-06-21 | Ind Tech Res Inst | Dichroic dye, composition thereof, and liquid crystal composition and liquid-crystal display element containing the same |
| US7601844B2 (en) * | 2006-01-27 | 2009-10-13 | Bristol-Myers Squibb Company | Piperidinyl derivatives as modulators of chemokine receptor activity |
| FR2903405B1 (fr) | 2006-07-04 | 2011-09-09 | Pasteur Institut | Composes a effet potentialisateur de l'activite de l'ethionamide et leurs applications |
| TW200938203A (en) * | 2007-12-17 | 2009-09-16 | Intervet Int Bv | Anthelmintic agents and their use |
| EP2234643B1 (en) | 2007-12-21 | 2013-01-09 | ETH Zurich | Composition for treatment of tuberculosis |
| US20110118262A1 (en) | 2008-07-08 | 2011-05-19 | Boehringer Ingelheim International Gmbh | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors |
| US8394818B2 (en) * | 2008-10-17 | 2013-03-12 | Dana-Farber Cancer Institute, Inc. | Soluble mTOR complexes and modulators thereof |
| FR2939135B1 (fr) * | 2008-12-02 | 2010-12-03 | Galderma Res & Dev | Nouveaux composes 4-(azacycloalkyl)-benzene-1,3-diol comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique |
| CN102458393B (zh) | 2009-06-25 | 2014-08-20 | 生物验证系统股份公司 | 治疗肺结核的组合物 |
| KR101179508B1 (ko) * | 2010-06-24 | 2012-09-07 | 한국과학기술연구원 | 1,6-이치환-3-아미노-4,5,6,7-테트라하이드로-1Ｈ-피라졸로［3,4-ｃ］피리딘-7-온 화합물 및 이 화합물의 제조방법 |
| US8962658B2 (en) | 2011-10-25 | 2015-02-24 | Universite De Droit Et De La Sante De Lille 2 | Fluoralkylcarbonyl-oxadiazoles |
| CN104684906B (zh) * | 2012-05-11 | 2017-06-09 | 艾伯维公司 | Nampt抑制剂 |
| KR102137517B1 (ko) | 2012-07-20 | 2020-07-24 | 바이엘 파마 악티엔게젤샤프트 | 신규 5-아미노테트라히드로퀴놀린-2-카르복실산 및 그의 용도 |
| FR3000064A1 (fr) | 2012-12-21 | 2014-06-27 | Univ Lille Ii Droit & Sante | Composes de type spiroisoxazoline ayant une activite potentialisatrice de l'activite d'un antibiotique-composition et produit pharmaceutiques comprenant de tels composes |
-
2012
- 2012-12-21 FR FR1203548A patent/FR3000065A1/fr not_active Withdrawn
-
2013
- 2013-12-20 KR KR1020157019623A patent/KR20150138152A/ko not_active Ceased
- 2013-12-20 SG SG11201504492UA patent/SG11201504492UA/en unknown
- 2013-12-20 PE PE2015001024A patent/PE20151327A1/es unknown
- 2013-12-20 MA MA38275A patent/MA38275B1/fr unknown
- 2013-12-20 EA EA201590828A patent/EA028076B1/ru not_active IP Right Cessation
- 2013-12-20 EP EP13814948.9A patent/EP2935212B1/fr active Active
- 2013-12-20 JP JP2015548640A patent/JP6515035B2/ja active Active
- 2013-12-20 US US14/653,669 patent/US9957249B2/en active Active
- 2013-12-20 AU AU2013366503A patent/AU2013366503B2/en not_active Ceased
- 2013-12-20 MX MX2015008029A patent/MX2015008029A/es unknown
- 2013-12-20 UA UAA201505250A patent/UA117922C2/uk unknown
- 2013-12-20 BR BR112015014279A patent/BR112015014279A2/pt not_active Application Discontinuation
- 2013-12-20 WO PCT/EP2013/077732 patent/WO2014096378A1/fr not_active Ceased
- 2013-12-20 CA CA2895606A patent/CA2895606A1/fr not_active Abandoned
- 2013-12-20 CN CN201380067137.2A patent/CN104955804B/zh active Active
- 2013-12-20 GE GEAP201313844A patent/GEP20186857B/en unknown
-
2015
- 2015-05-25 TN TNP2015000202A patent/TN2015000202A1/fr unknown
- 2015-05-25 ZA ZA2015/03719A patent/ZA201503719B/en unknown
- 2015-06-12 CL CL2015001640A patent/CL2015001640A1/es unknown
- 2015-06-17 CR CR20150319A patent/CR20150319A/es unknown
- 2015-06-18 IL IL239504A patent/IL239504B/en not_active IP Right Cessation
- 2015-06-19 PH PH12015501427A patent/PH12015501427A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016503778A5 (enExample) | ||
| ZA202006378B (en) | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof | |
| MX385731B (es) | Compuestos de biaril-monobactam y métodos de uso de los mismos para el tratamiento de infecciones bacterianas. | |
| CY1118292T1 (el) | Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων | |
| JP2016514159A5 (enExample) | ||
| EP4420732A3 (en) | Fused ring heteroaryl compounds and their use as trk inhibitors | |
| RU2015146957A (ru) | Производные доластатина 10 и ауристатинов | |
| JP2011529054A5 (enExample) | ||
| JP2016501250A5 (enExample) | ||
| JP2015516427A5 (enExample) | ||
| JP2011513305A5 (enExample) | ||
| JP2015024998A5 (enExample) | ||
| JP2015520769A5 (enExample) | ||
| JP2016516043A5 (enExample) | ||
| JP2013056919A5 (enExample) | ||
| JP2015504081A5 (enExample) | ||
| JP2014502988A5 (enExample) | ||
| MX2016008665A (es) | Derivado basado en 1,2-naftoquinona y metodo de preparacion del mismo. | |
| JP2015521195A5 (enExample) | ||
| BR112013031121A2 (pt) | composto de acordo com a fórmula i a v, ou um sal farmaceuticamente aceitável, solvato, polimorfo, ou pró-droga do mesmo; composto; polimorfo de sal cloridrato de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h-pirrol-3-il)tiazol-2-il)acetamida (fórmula i); ingrediente ativo constituído do mesmo; composição farmacêutica; polimorfo de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)1h-pirrol-3-il)tiazol-2-il)fenil)acetamida (fórmula i); ingrediente ativo constituído do mesmo; uso de um composto ou sal farmaceuticamente aceitável, solvato, polimorfo ou pró-droga do mesmo e uso de um polimorfo ou ingrediente ativo de sal cloridrato de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h-pirrol-3-il)tiazol-2il)tiazol-2-il)fenil)acetamida (fórmula i) e uso de um polimorfo ou ingrediente ativo de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h1pirrol-3-il)tiazol-2-il)fenil)acetamida(fórmula i) na fabricação de um medicamento | |
| JP2020505440A5 (enExample) | ||
| CO2020012353A2 (es) | Compuestos de pirazol sustituidos con heteroarilo y uso farmacéutico de los mismos | |
| MX388175B (es) | Compuestos terapéuticos y métodos para utilizarlos | |
| AR108712A1 (es) | (5r)-5-[3-[(3s)-4-(4-cloro-3-metoxi-5-metil-fenil)-3-metil-piperazin-1-il]-3-oxo-propil]-5-metil-imidazolidin-2,4-diona, composiciones farmacéuticas del mismo para el tratamiento de trastornos inflamatorios y osteoartritis | |
| MX385203B (es) | Compuestos y métodos para tratar infecciones bacterianas. |